Tel Aviv - Delayed Quote • ILA
Evogene Ltd. (EVGN.TA)
At close: April 25 at 2:24 PM GMT+3
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
5,640.00
5,640.00
1,675.00
930.00
1,040.00
Cost of Revenue
1,692.00
1,692.00
909.00
767.00
574.00
Gross Profit
3,948.00
3,948.00
766.00
163.00
466.00
Operating Expense
30,456.00
30,456.00
27,707.00
31,116.00
25,280.00
Operating Income
-26,508.00
-26,508.00
-26,941.00
-30,953.00
-24,814.00
Net Non Operating Interest Income Expense
975.00
975.00
-237.00
-270.00
-393.00
Other Income Expense
-454.00
-454.00
-2,576.00
791.00
-967.00
Pretax Income
-25,987.00
-25,987.00
-29,754.00
-30,432.00
-26,174.00
Tax Provision
-33.00
-33.00
90.00
13.00
32.00
Net Income Common Stockholders
-23,879.00
-23,879.00
-26,638.00
-27,793.00
-23,374.00
Diluted NI Available to Com Stockholders
-23,879.00
-23,879.00
-26,638.00
-27,793.00
-23,374.00
Basic EPS
-0.52
-0.52
-0.65
-0.69
-0.83
Diluted EPS
-0.52
-0.52
-0.65
-0.69
-0.83
Basic Average Shares
45,685.62
45,685.62
41,210.18
40,433.30
28,158.78
Diluted Average Shares
45,685.62
45,685.62
41,210.18
40,433.30
28,158.78
Total Operating Income as Reported
-26,508.00
-26,508.00
-26,941.00
-30,953.00
-24,814.00
Total Expenses
32,148.00
32,148.00
28,616.00
31,883.00
25,854.00
Net Income from Continuing & Discontinued Operation
-23,879.00
-23,879.00
-26,638.00
-27,793.00
-23,374.00
Normalized Income
-23,425.58
-23,425.58
-24,654.48
-28,402.07
-22,629.41
Interest Income
1,248.00
1,248.00
182.00
291.00
230.00
Interest Expense
115.00
115.00
165.00
315.00
237.00
Net Interest Income
975.00
975.00
-237.00
-270.00
-393.00
EBIT
-25,872.00
-25,872.00
-29,589.00
-30,117.00
-25,937.00
EBITDA
-23,260.00
-23,260.00
-27,009.00
-27,883.00
-23,210.00
Reconciled Cost of Revenue
1,692.00
1,692.00
909.00
767.00
574.00
Reconciled Depreciation
2,612.00
2,612.00
2,580.00
2,234.00
2,727.00
Net Income from Continuing Operation Net Minority Interest
-23,879.00
-23,879.00
-26,638.00
-27,793.00
-23,374.00
Total Unusual Items Excluding Goodwill
-454.00
-454.00
-2,576.00
791.00
-967.00
Total Unusual Items
-454.00
-454.00
-2,576.00
791.00
-967.00
Normalized EBITDA
-22,806.00
-22,806.00
-24,433.00
-28,674.00
-22,243.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-0.58
-0.58
-592.48
181.93
-222.41
12/31/2020 - 6/13/2007
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
CANF.TA Can-Fite BioPharma Ltd.
2.7000
+3.85%
PPBT.TA Purple Biotech Ltd
20.50
+1.99%
CGEN.TA Compugen Ltd.
764.00
+1.93%
BLRX.TA BioLineRx Ltd.
16.40
-2.38%
PPBT Purple Biotech Ltd
0.4900
-2.00%
ORMP Oramed Pharmaceuticals Inc.
2.4600
+6.96%
GNTA Genenta Science S.p.A.
2.5900
-11.60%
PLUR Pluri Inc.
5.36
+2.23%
MURA Mural Oncology plc
3.5800
+1.42%
PHRM.CN PharmaTher Holdings Ltd.
0.2400
-2.04%